Mark Nedelman

Mark Nedelman is a seasoned professional with extensive experience in the biomedical and therapeutic industries. Currently serving as a Board Trustee at XenoTherapeutics and a Consultant at CeleCor Therapeutics, Mark has played a critical role in overseeing the development of Zalunfiban for heart attack treatment. Previous leadership positions include CEO of Biomedical Research Models, Inc. (2016-2023) and President & CEO of EKAM IMAGING, INC. (2010-2018), along with significant contributions as Sr. Director of Business Development at SelectX Pharmaceuticals and General Manager at Charles River Laboratories. Mark's earlier experience includes a key role at Centocor in preclinical pharmacology and research at Massachusetts General Hospital. Mark holds an MBA from Northeastern University and advanced degrees in Biology from the University of Cincinnati.